^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
LCAR-AIO
i
Other names: LCAR-AIO, Tri-specific CD19xCD20xCD22 VHH CAR-T cells, LCARAIO, LCAR AIO
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Legend Biotech
Drug class:
CD19-targeted CAR-T immunotherapy, CD20-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
Related drugs:
2ms
A Study of LCAR-AIO in Subjects with Relapsed/Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
P1, N=34, Not yet recruiting, Wuhan Union Hospital, China
New P1 trial
|
LCAR-AIO
7ms
A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia (clinicaltrials.gov)
P1, N=20, Active, not recruiting, Institute of Hematology & Blood Diseases Hospital, China | Recruiting --> Active, not recruiting | N=34 --> 20
Enrollment closed • Enrollment change
|
CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
|
CD19 expression
|
cyclophosphamide • LCAR-AIO
over2years
A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia (clinicaltrials.gov)
P1, N=34, Recruiting, Institute of Hematology & Blood Diseases Hospital | Not yet recruiting --> Recruiting
Enrollment open
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 expression
|
cyclophosphamide • LCAR-AIO
over2years
Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov)
P1, N=34, Recruiting, Qiu Lugui
New P1 trial
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 expression
|
cyclophosphamide • LCAR-AIO
almost3years
A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia (clinicaltrials.gov)
P1, N=34, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital
New P1 trial
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 expression
|
cyclophosphamide • LCAR-AIO
3years
Tri-Specific CD19xCD20xCD22 VHH CAR-T Cells (LCAR-AIO) Eradicate Antigen-Heterogeneous B Cell Tumors, Enhance Expansion, and Prolong Persistence in Preclinical In Vivo Models (ASH 2021)
Based on in vitro and in vivo preclinical data, tri-specific CD19xCD20xCD22 VHH CAR-T can be effective targeting tumors lack of CD19 expression, therefore, it has the potential of treating relapsed patients with prior CD19 CAR-T therapy. The feasibility of making tri-specific CAR-T would help to extend this technology to solid cancers where heterogeneity poses a major challenge at current stage.
Preclinical • CAR T-Cell Therapy • IO biomarker
|
IFNG (Interferon, gamma)
|
CD20 expression • CD19 expression
|
LCAR-AIO
Share via
